A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > BUSINESS
BUSINESS
- Takeda Gets China OK for Shire Takeover
September 18, 2018
- Sekisui Chemical Hooks Up with Regenerative Medicine Upstart
September 14, 2018
- Shionogi Grabs Rights to Rohto’s Cell-Based Hepatic Cirrhosis Therapy
September 14, 2018
- Poxel Forms Japan Outpost, Hitches Janssen’s Kaneko as Country Chief
September 14, 2018
- I/O in Lung Cancer - 5: Roche Looks Beyond Tecentriq, Laying Foundation for Next-Gen Immunotherapies
September 13, 2018
- Ex-AZ Exec Nogami Tapped to Lead Takeda Consumer Healthcare
September 13, 2018
- Kowa Continues Heavy GP Pitch for Parmodia in July: Anterio
September 13, 2018
- Nippon Shinyaku Eyes Conditional Early OK for Sakigake DMD Drug, Daiichi Sankyo Redoing PI/II for Its Antisense
September 12, 2018
- Quizartinib Earns Japan Orphan Status for AML: Daiichi Sankyo
September 12, 2018
- Avastin Best-Selling Drug in Japan in August: Encise Snapshot
September 12, 2018
- Risankizumab Hits Primary Endpoint in Japan PII/III Study with Psoriasis Vulgaris Patients: AbbVie
September 11, 2018
- Power Back On at Drug Makers’ Hokkaido Plants
September 11, 2018
- Tremfya Meets Primary Endpoint in Japan PIII Study for Palmoplantar Pustulosis: Janssen
September 11, 2018
- Ethical Drug Sales Up 3.6% in July: Crecon
September 11, 2018
- Shionogi Loses HIV Patent Battle against MSD
September 10, 2018
- Hokkaido Quake Hits Wholesaler Price Negotiations as Sept. Deadline for Medical Fee Cuts Looms
September 10, 2018
- Sanofi to Focus on Increasing Prescriptions of Lantus XR Based on Results of Head-to-Head Comparison Study
September 10, 2018
- Xofluza Cuts Flu Symptoms, Vial Loads: Shionogi
September 7, 2018
- Ono to Divide Oncology Sales Force into Two Units as Opdivo Label Expands
September 7, 2018
- Giant Quake Disrupts Drug Production, Shipments in Hokkaido; Distributors Scramble to Ensure Supplies
September 7, 2018
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…